Abstract: Ovarian cancer (OC) has been the most fatal gynecological disease that threatens women's health. Surgery and platinum-based chemotherapy are the basic ovarian cancer treatments that can improve survival, but the five-year survival rate has not improved because of delayed diagnosis, drug resistance, and recurrence. Novel treatments are needed to improve the prognosis and survival rate of ovarian cancer patients. In recent years, adoptive cell therapy (ACT) has received increasing attention as an emerging therapeutic strategy in the treatment of solid tumors including OC. ACT has shown promising results in many preclinical and clinical trials of OC. The application of ACT depends on different effector cells, such as lymphokineactivated killer (LAK) cells, tumor-infiltrating lymphocytes (TILs), and genetically modified T cells. In this review, we focus on adoptive immunotherapies in ovarian cancer and summarize completed and ongoing preclinical/clinical trials. The future development directions and obstacles for ACT in OC treatment are discussed.
Introduction
(ACT). [22] [23] [24] Among them, ACT has attracted increasing attention because a large number of specific effector cells against tumor cells results in a quick therapeutic effect and minimizes impact on the internal environment than other therapies. ACT relies on intravenous infusion of autologous immune cells after stimulation/modification and expansion in vitro to improve autologous antitumor response in tumor patients [ Figure 1 ]. In 1965, Mathé et al confirmed that adoptive immunotherapy had an obvious effect on acute leukemia in a murine experiment and clinical trial. 25 Research on ACT for the treatment of hematological malignancies is constantly evolving and developing. 26, 27 In 2002, a clinical trial showed that adoptive cell immunotherapy was effective for solid tumors (metastatic melanoma) 28 and ongoing clinical trials have confirmed this. 29, 30 Since OC was not originally considered to be an The progression-free and overall survival of complete resection (ideally with no macroscopic residual disease) are improved compared with so-called optimal and suboptimal debulking resection.
7 Chemotherapy 1. Chemotherapy is a milestone in the treatment of ovarian cancer because it improves the outcome in women with ovarian cancer. It can help to achieve no residual tumor (R0) after primary debulking surgery (PDS), or to treat patients by neoadjuvant chemotherapy (NACT). 3. However, there is also evidence that bevacizumab has toxicity and side effects such as gastrointestinal (GI) perforation, surgery and wound-healing complications, and hemorrhage.
4. Only a subset of patients will benefit from anti-angiogenic agents
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Immunotherapy Tumor immunotherapy, such as anti-PD-L1/PD-1 therapies and adoptive therapy, have subsequently demonstrated significant anti-tumor effects. Although immunotherapy is still in its infancy in the clinical treatment of ovarian cancer, many promising preclinical experiments indicate its potential.
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OncoTargets and Therapy 2019:12 also shown promising therapeutic effects in their previous in vivo experiments in mice; 34 however, they also mentioned that high-dose IL-2 promotes the secretion of toxic cytokines by helper T cells, which is harmful to patients. Grimm et al also described this problem. 35 Although LAK cell adoptive immunotherapy has a very broad-spectrum anti-tumor effect, the safe application of high-dose IL-2 is still problematic.
NK Cells
NK cells are part of the innate immune response and are key effectors in cancer immunosurveillance. 36 They can defend against cancer development and metastasis without restricting the expression of MHC molecules. 37 49 A clinical phase II trial to determine whether radiofrequency ablation (RFA) and cytokine-induced killer cell (CIK) infusion can prolong survival in patients with OC is also underway (NCT02487693).
MHC-Dependent Adoptive Immunotherapy TILs
TILs are endogenous autologous T cells isolated from tumor tissues with certain tumor specificity and MHC restriction. Adoptive immunotherapy with TILs has a response rate of about 50% in melanoma patients. 30 55 recently discovered an effective method for isolating and expanding TILs from OC. Surprisingly, the expanded TILs retain the ability to recognize autologous tumor cells in vitro. 55 Although numerous studies have indicated the promise of TILs adoptive immunotherapy for OC, problems remain that limit its development. For example, the anti-tumor effect of TILs is limited by the fact that unselected TILs in OC usually contain only a small number of tumor-reactive T cells. In addition, the greater financial support required for isolation and expansion of tumor-specific TILs and reperfusion into patient limits their clinical application.
CAR-T Cells And TCR-T Cells
Although TIL cell adoptive immunotherapy is a promising treatment for OC, the method of isolating and manufacturing TILs is labor intensive and successful in only a subset of patients, which limits its therapeutic effect and clinical application. 56, 57 In order to improve the therapeutic potential, genetically modified peripheral blood lymphocytes that exhibit tumor antigen specificity have received more and more attention. Genetically modified T cells can express a chimeric antigen receptor (CAR) or a tumorantigen specific T-cell receptor (TCR).
CAR-T Cell Therapy
CAR-T cells are T lymphocytes that have been genetically modified to express an engineered T cell receptor that is able to recognize tumor-specific antigens MHC unrestrictedly and activate the immune response. The CAR comprises four main parts: the extracellular antigen-binding domain, the spacer domain (hinge domain), the transmembrane domain, and the intracellular T cell activation/signaling domain. The extracellular antigen-binding domain, also known as the ectodomain, is derived from the light and heavy chains of the antibody and is a single-chain variable fragment (scFv) that can recognize tumor-specific antigens on cell surface in an MHC-unrestricted manner. [58] [59] [60] The CAR-T cell structure design has been constantly updated, through four generations, producing CAR-T cells that survive longer in vivo and have stronger killing ability [ Figure 3 ]. The first generation of CAR-T cells only contained the extracellular scFv antigen recognition region and the intracellular CD3ζ chain signal region. To improve the proliferation and persistence of CAR-T cells, the costimulatory molecules such as CD28 and OX-40/4-1BB (CD134/CD137) were added in the second and third generation. The fourth generation is characterized by releasing cytokines like IL-12 and IL-15, which enhance immune response.
61,62
The most exciting results with CAR-T cell therapy have been achieved in hematological tumors. In a phase I clinical trial conducted by Park et al, 63 promising results suggesting that this approach may be effective for the treatment of OC, and a parallel clinical trial is ongoing. 65 MUC16 plays an important role in the progression and metastasis of OC and has become a key target for OC treatment. 66 Mesothelin is an antigen target that is overexpressed in OC. 67 The expression of mesothelin is associated with the prognosis of OC; hence, mesothelin is both a therapeutic target for OC and a prognostic marker. 68 The results of preliminary trials are promising, and more clinical trials on CAR-T cell therapy targeting mesothelin are still ongoing, such as NCT03692637 and NCT03814447. Folate receptor-α (FRα) is a glycosylphosphatidylinositol-anchored protein that expressed on the surface of normal ovarian cells. FRα is also overexpressed on the surface of malignant epithelial cancer cells, making it a potential target for the treatment of OC.
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The safety and efficacy of CAR-T cell therapy targeting FRα are supported by preclinical studies and phase I clinical trials. 72, 73 Another clinical trial (NCT03585764) is also underway. Other antigens such as HER2 and CD133 have also been tested in preclinical animal models for OC therapy (NCT01935843, NCT02541370).
Although CAR-T cell therapy has shown great potential in the treatment of OC, it still faces many problems that remain to be solved. The CAR target antigen is also expressed in some normal tissue, resulting in immunemediated rejection that is known as an "on-target, offtumor" response. This rejection can even cause damage to vital organs such as the liver and lungs. 74, 75 Also, the potentially immunosuppressive environment in OC, including the highly immunosuppressive ascites, will prevent T cells from effectively infiltrating into tumor cells and dysfunctional T cells. CAR-T cell adoptive immunotherapy also has some common problems of ACT treatment, such as cytokine release syndrome and a more effective T cell transport pathway. In conclusion, there are both hopes and challenges in the treatment of OC by CAR. Further research is necessary to improve the safety and efficacy of CAR-T cell therapy in OC.
TCR-T Cell Therapy
TCRs are characteristic markers on the surface of T cells that recognize specific antigens. 76, 77 TCR-T cells are T cells that express a genetically engineered TCR alpha and beta chain pair that can recognize tumor-specific antigens. TCR-T cell treatment has been successful in patients with malignant cancer such as colorectal carcinoma, 78 metastatic melanoma, 79 and multiple myeloma. 80, 81 Genetically modified TCR-T cells are also considered as a potentially promising treatment for OC patients. In OC, the TCR target antigens include MAGE-A4, WT1, and NY-ESO-1, with NY-ESO-1 being widely studied. New York esophageal squamous cell carcinoma-1 (NY-ESO-1) is an 18 kDa protein that can be detected in normal testis, fetal ovary, and placenta. 82, 83 However, NY-ESO-1 antibodies can also be detected in the serum of ovarian cancer, lung cancer, breast cancer, bladder cancer, esophageal cancer, as well as melanoma patients. 85 As observed with CAR-T cells, the "ontarget, off-tumor" response occurs when TCR-T cells are infused, due to the expression of the same antigen on normal tissue, and the infused TCR-T cells also induce the occurrence of cytokine release syndrome (CRS).
Although both TCR-T cells and CAR-T cells are genetically modified, they have several differences. Since TCRs can recognize epitopes from both intracellular and cell surface antigens of tumor cells via TAA/MHC complex, tumor-specific TCRs can only be used in patients with the specific MHC or HLA allele. In contrast, CAR recognition does not rely on peptide processing or MHC molecules; hence, CARs can only recognize tumor surface antigens; however, all surface target molecules may become potential CAR trigger epitopes. 60 Obstacles For ACT In OC
Immunosuppressive Tumor Microenvironment
Immune suppression in tumor microenvironment (TME) is mediated by three main factors: 86 1) immunosuppressive cells in the TME; 2) cytokines and enzymes released from the tumor or myeloid cells; and 3) barriers. An immunosuppressive TME seriously affects the therapeutic effect of ACT on tumors, especially in OC, 87 which can build a highly suppressive environment in the peritoneal cavity. T-regulatory cells (Tregs) and myeloid-derived suppressor cells (MDSCs) are both important immunosuppressive cells in the OC TME. 88, 89 Tregs can induce immunosuppressive cytokines such as IL-10 and TGF-β to suppress the function of tumor-infiltrating cytotoxic T cells in the OC environment. 90, 91 MDSCs express high levels of substances such as arginase, inducible nitric oxide synthase (iNOS), and reactive oxygen species (ROS) to inhibit T-cell function. 92, 93 In order to reduce immunosuppression in TME, non-myeloablative chemotherapy can be used to decrease the number of Tregs and suppressive cellular cytokines. 94 This can also be achieved by combinations of ACT with immune checkpoint inhibitors and targeted therapies. 95 Some cytokines and enzymes released from the tumor or myeloid cells also can suppress the immune response. High expression of vascular endothelial growth factor (VEGF), which is expressed in most OC, 96, 97 can recruit MDSCs to the tumor site and inhibited tumor immunity in ovarian carcinoma. 98 In tumor cells, the high expression of TGF-β will inhibit the function of human memory CD8 + T cells and tumor-infiltrating lymphocytes. 99 Indoleamine 2,3-dioxygenase (IDO) is an enzyme that catalyzes the degradation of tryptophan, which in turn inhibits T cell proliferation. In addition, IDO can directly inhibit T cells and enhance local Treg-mediated immunosuppression. 100 To solve the immunosuppression caused by these cytokines and enzymes, we can combine antagonists and blocking antibodies for different targets with ACT treatment. Tumor vasculature and tumor stroma are both common barriers that prevent homing of effector T cells.
101,102
Leung et al suggested that cancer-associated fibroblasts (CAFs) can upregulate the lipoma-preferred partner (LPP) and this was correlated with survival and chemoresistance in patients with OC. 102 They demonstrate the importance of CAF-endothelial cell crosstalk signaling in cancer treatment and the strategy of using LPP targeting siRNA in combination with cytotoxic drugs to improve treatment efficacy. Antiangiogenic agents are also being used to normalize the tumor vasculature and reduce the tumor metastasis in OC. 6 A recent study showed that losartan has the effect of reducing collagen content as well as improving perfusion and relieving tumor hypoxia, and this is helpful to enhance chemotherapeutic efficacy in OC models. 103 
Cytokine Release Syndrome (CRS)
CRS is a potentially life-threatening acute inflammation that occurs after ACT infusion in hematologic and solid tumor patients. [104] [105] [106] The typical clinical manifestations of CRS include constitutional symptoms like fever, malaise, anorexia, and myalgias, 107, 108 and organic damage like cardiac dysfunction, respiratory distress syndrome, and renal/hepatic/neurologic toxicity. 107 CRS is caused by a massive cytokine release by the infused T On-Target, Off-Tumor Toxicity "Tumor-specific" antigens are also commonly expressed in normal tissues, which results in an on-target, off-tumor immune response after stimulation of T cells in ACT. If these antigens are expressed in vital organs, such as heart, liver, and kidney, they will cause fatal damage. 74, 75 The fundamental solution to this problem is to select tumorspecific antigens that are not expressed in normal tissues, but this is difficult. To overcome this, Kloss et al proposed a method where T cells are transduced with both a CAR, offering suboptimal activation upon binding of one antigen, and a chimeric costimulatory receptor (CCR) that recognizes a second antigen. 111 This technology has made progress in OC. Lanitis et al generated trans-signaling T cells with two distinct CARs: anti-Meso scFv-CD3ζ and anti-FRα scFv-CD28. 112 Both FRα and mesothelin show high expression in OC tissue, compared to much lower expression in normal tissues. The trans-signaling CAR strategy can more accurately identify tumor cells and diminish damage to normal tissues.
Future Perspective
Many clinical trials of ACT for ovarian cancer are ongoing [ Table 2 ]. However, owing to the complexity of the OC tumor microenvironment and the human immune system, there are still many problems to be solved in the ACT treatment of OC. For example, how to reduce costs while ensuring efficient production of effector cells; and how infused T cells could home in on the tumor site and infiltrate it more accurately. Furthermore, many of the current clinical and preclinical experiments lack randomness, and more randomized trials are needed to confirm that ACT can improve overall survival (OS) or progression-free survival (PFS) in patients with ovarian cancer. Nonetheless, in preclinical and clinical trials, the efficacy of ACT in OC is promising. Therefore, ACT still shows potential to become the new effective therapy for OC if we can address the abovementioned obstacles to reduce toxicity and improve the efficiency of ACT. The immune response inhibition caused by the tumor microenvironment can be reduced by combining the application of immunological checkpoint inhibitors or anti-angiogenesis agents, enabling improved effector cell function. In addition, new technology is evolving that utilizes two different CARs on T cells, enabling effector cells to more accurately identify tumor cells and improving their antitumor efficacy. Cell metabolism plays an important role in the anti-tumor effect of immune cells. Increasingly, studies have shown that the regulation of immune cell metabolism can affect the immune response; [116] [117] [118] therefore, regulation of the effector cell metabolism process may be another approach to improve the anti-tumor effect and efficacy of ACT. Further refinement of technologies will hopefully generate more successful treatment methods for ovarian cancer.
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